Patients with NSCLC may display a low ratio of p.T790M <i>vs.</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatmentMarzia Del Re, Romano Danesi, Iacopo Petrini et al.|Oncotarget|2017Cited by 12